Glaukos
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell Glaukos and other ETFs, options, and stocks.About GKOS
Glaukos Corp. is an ophthalmic medical technology and pharmaceutical company, which focuses on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It engages in development and commercialization of therapies across several end markets within ophthalmology.
CEOThomas William Burns
CEOThomas William Burns
Employees995
Employees995
HeadquartersAliso Viejo, California
HeadquartersAliso Viejo, California
Founded1998
Founded1998
Employees995
Employees995
GKOS Key Statistics
Market cap5.04B
Market cap5.04B
Price-Earnings ratio-46.52
Price-Earnings ratio-46.52
Dividend yield—
Dividend yield—
Average volume1.82M
Average volume1.82M
High today$102.80
High today$102.80
Low today$85.85
Low today$85.85
Open price$95.50
Open price$95.50
Volume4.83M
Volume4.83M
52 Week high$163.71
52 Week high$163.71
52 Week low$73.16
52 Week low$73.16
GKOS News
Seeking Alpha 18h
Glaukos outlines $600M–$620M 2026 revenue outlook as Epioxa launch and iDose TR drive growthEarnings Call Insights Glaukos outlines $600M–$620M 2026 revenue outlook as Epioxa launch and iDose TR drive growth Oct. 30, 2025 12:07 AM ET Glaukos Corporatio...
TipRanks 1d
Glaukos reports Q3 EPS (16c), consensus (26c)Reports Q3 revenue $133.5M, consensus $122.6M. “Our record third quarter results reflect continued strong momentum in our business driven by successful global e...
Simply Wall St 6d
Glaukos: Evaluating Valuation Following FDA Approval of Epioxa Topical Treatment for KeratoconusGlaukos, a leader in ophthalmic therapies, has just secured FDA approval for Epioxa, a new incision-free topical treatment for keratoconus. This milestone repre...
Analyst ratings
93%
of 15 ratingsBuy
93.3%
Hold
0%
Sell
6.7%
People also own
Based on the portfolios of people who own GKOS. This list is generated using Robinhood data, and it’s not a recommendation.